Literature DB >> 16357836

Bone marrow angiogenesis in multiple myeloma.

A Vacca1, D Ribatti.   

Abstract

Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. It is induced by plasma cells via angiogenic factors with the transition from monoclonal gammopathy of undetermined significance (MGUS) to MM, and probably with loss of angiostatic activity on the part of MGUS. The pathophysiology of MM-induced angiogenesis is complex and involves both direct production of angiogenic cytokines by plasma cells and their induction within the microenvironment. The latter are secreted by stromal cells, endothelial cells (EC) and osteoclasts, and promote plasma cell growth, survival and migration, as well as paracrine cytokine secretion and angiogenesis in the bone marrow milieu. Angiogenesis is also supported by inflammatory cells following their recruitment and activation by plasma cells. Finally, circulating EC and endothelial precursor cells (EPC) contribute to the neovascularization, and the presence of EPC suggests that vasculogenesis (new vessel formation from EPC) may also contribute to the full MM vascular tree.

Entities:  

Mesh:

Year:  2006        PMID: 16357836     DOI: 10.1038/sj.leu.2404067

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  66 in total

1.  Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Mol Pharm       Date:  2011-10-12       Impact factor: 4.939

2.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

3.  Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

Authors:  M A Frassanito; L Rao; M Moschetta; R Ria; L Di Marzo; A De Luisi; V Racanelli; I Catacchio; S Berardi; A Basile; E Menu; S Ruggieri; B Nico; D Ribatti; R Fumarulo; F Dammacco; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2013-09-02       Impact factor: 11.528

Review 4.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

5.  Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.

Authors:  Maria Ozerova; Yulia Nefedova
Journal:  Leuk Lymphoma       Date:  2019-01-02

6.  Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Authors:  M Bhutani; B Turkbey; E Tan; T J Kemp; L A Pinto; A R Berg; N Korde; A R Minter; B M Weiss; E Mena; L Lindenberg; O Aras; M P Purdue; J N Hofmann; S M Steinberg; K R Calvo; P L Choyke; I Maric; K Kurdziel; O Landgren
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

7.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  The role of microenvironment in tumor angiogenesis.

Authors:  Domenico Ribatti; Angelo Vacca
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

9.  Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Sharmin Khan; Shmuel Yaccoby
Journal:  Cancer Lett       Date:  2009-05-15       Impact factor: 8.679

Review 10.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.